Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar

Bahattin Taylan KOÇ, (Adnan Menderes Üniversitesi, Veteriner Fakültesi, Viroloji Anabilim Dalı, Aydın, Türkiye)
Nural EROL (Adnan Menderes Üniversitesi, Veteriner Fakültesi, Viroloji Anabilim Dalı, Aydın, Türkiye)
Harran Üniversitesi Veteriner Fakültesi Dergisi
11 3
Yıl: 2016 Cilt: 5 Sayı: 2 Sayfa Aralığı: 196 - 201 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar

Öz:
Onkolitik viroterapi, viruslar ile kanser tedavisi konsepti, yakın geçmiş ve günümüzde ortaya çıkan ve kanserle savaşta yeni bir imkân sağlayan önemli bir mekanizmadır. Virusların genel anlamda replikasyonu bölünme ve çoğalma kinetiği yüksek hücrelere affinite göstermesinden yararlanılarak oluşturulan bu tedavi konseptinde bazı virus ve aileleri ön plana çıkmaktadır. Bunlar diğer viruslara oranla tümör hücrelerine daha fazla hedeflenmektedir. Ayrıca gen mühendisliği ile yapılan tasarım viruslarla da aynı hedeflenme ve terapi uygulanabilinmektedir. İşte bu virusların hepsine onkolitik viruslar adı verilmektedir. Günümüzde ilaç haline getirilip faz III çalışmalarından başarıyla çıkan bazı onkolitik viruslar kanser tedavisinde umut verici sonuçlar ortaya koymuştur. Burdan yola çıkarak bu derlemede onkolitik viroterapi ve bazı onkolitik viruslar ile yapılan terapötik uygulamalar ele alınacaktır.
Anahtar Kelime:

Konular: Ziraat Mühendisliği

Oncolytic Virotherapy and Anti-Tumoral Applications With the Some Oncolytic Viruses

Öz:
Oncolytic virotherapy, the concept of treating cancer with viruses, is an important mechanism that provides an emerging opportunity in the struggle against cancer in recent past and nowadays. Generally, some viruses and their families stand out in this generated treatment concept utilizing by replications of viruses, exhibit greater affinitiy to cell which being greater of division and growth kinetics. These are extensively targeted to tumor cells compared to other viruses. Also same gene targeting and therapy strategy might be applied with designed viruses by gene engineering. Here, all of these viruses is named oncolytic viruses. Nowadays, some oncolytic viruses, formed as the drug, from phase III studies successfully have demonstrated promising results in the treatment of cancer. Based on this review, oncolytic virotherapy and its therapeutic applications with some oncolytic viruses will be discussed.
Anahtar Kelime:

Konular: Ziraat Mühendisliği
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • Alvarez-Breckenridge CA, Choi BD, Suryadevara CM, Chiocca EA, 2015: Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection. Curr Opin Virol, 13, 25-32.
  • Asada T, 1974: Treatment of human cancer with mumps virus. Cancer, 34, 907-1928.
  • Bangari DS, Shukla S, Mittal SK, 2005: Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Bioph Res Co, 327, 960-966.
  • Bell J, McFadden G, 2014: Viruses for tumor therapy. Cell Host Microbe, 15(3), 260-265.
  • Bourke MG, Salwa KJ, Harrington MJ, Kucharczyk MJ, Forde PF, Kruijf, Soden D, Tangney M, Collins JK, O'Sullivan GC, 2011: The emerging role of viruses in the treatment of solid tumours. Cancer Treatment Rev, 37(8), 618-632.
  • Buijs PRA, Verhagen JHE, van Eijck CHJ, van den Hoogen BG, 2015: Oncolytic viruses: From bench to bedside with a focus on safety. Hum. Vaccines Immunother, 11(7), 1573-1584.
  • Cancer Network 2015: Lawrence, L. "FDA Approves First Oncolytic Virus With New Melanoma Therapy". http://www.cancernetwork.com/melanoma/fda- approves-first-oncolytic-virus-new-melanoma- therapy, Erişim tarihi; 30.10.2015.
  • Cerullo V, Vaha-Koskela M, Hemminki A, 2012: Oncolytic adenoviruses: A potent form of tumor immunovirotherapy. Oncoimmunol, 1(6), 979-981.
  • Dorer DE, Nettelbeck DM, 2009: Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev, 61(7-8), 554-571.
  • Ferguson MS, Lemoine NR, Wang Y, 2012: Systemic delivery of oncolytic viruses: Hopes and hurdles. Adv Virol, doi: 10.1155/2012/805629.
  • Fukuhara H, Ino Y, Todo T, 2016: Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci, 107(10), 1373-1379.
  • Gentschev I, Patil SS, Petrov I, Cappello J, Adelfinger M, Szalay AA, 2014: Oncolytic virotherapy of canine and feline cancer. Viruses, 6(5), 2122-2137.
  • Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, Yin X, Yang S, Zeh HJ, Moss B, Lotze MT, Bartlett DL, 2005: The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res, 65, 9991-9998.
  • Hatcher EL, Hendrickson RC, Lefkowitz EJ, 2014: Identification of nucleotide-level changes impacting gene content and genome evolution in orthopoxviruses. J Virol, 88(23), 13651-13668.
  • Hu Y, Lee J, McCart JA, Xu H, Moss B, Alexander HR, Bartlett DL, 2001: Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy. J Virol, 75, 10300-10308.
  • Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J, 2006: Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticanc Ther, 6: 697-708.
  • Kanai R, Zaupa C, Sgubin D, Antoszczyk SJ, Martuza RL, Wakimoto H, Rabkin SD, 2012: Effect of ? 34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol, 86: 4420-4431.
  • Kelly E, Russell SJ, 2007: History of oncolytic viruses: genesis to genetic engineering. Mol Ther, 15(4), 651- 659.
  • Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D, Hwang TH, 2006: Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther, 14, 361-370.
  • Liu BL, Robinson M, Han Z-Q, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thorton T, Bullock P, Love CA, Coffin RS, 2003: ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther, 10: 292-303.
  • Lun X, Yang W, Alain T, Shi ZQ, Muzik H, Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL, Forsyth PA, 2005: Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res, 65, 9982- 9990.
  • Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL, 2012: Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol, 39(3), 296-304.
  • Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM, 1991: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 252, 854-856.
  • Mousset S, Rommelaere J, 1982: Minute virus of mice inhibits cell transformation by simian virus 40. Nature, 300, 537-539.
  • Newman W, Southam CM, 1954: Virus treatment in advanced cancer. A pathological study of fifty-seven cases. Cancer, 7(1), 106-118.
  • Okuno Y, Asada T, Yamanishi K, Otsuka T, Takahashi M, Tanioka T, Aoyama H, Fukui O, Matsumoto K, Uemura F, Wada A, 1978: Studies on the use of mumps virus for treatment of human cancer. Biken J, 21, 37-49.
  • Pack GT, 1950: Note on the experimental use of rabies vaccine for melanomatosis. AMA Arch Dermatol and Syphil, 62, 694-695.
  • Petrulio CA, Kaufman HL, 2006: Development of the PANVAC(TM)-VF vaccine for pancreatic cancer. Expert Rev Vaccines, 5(1), 9-19.
  • Russell SJ, Peng KW, Bell, JC, 2012: Oncolytic virotherapy. Nature Bio, 30(7), 658-670.
  • Senzer N, Nemunaitis J, 2009: A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther, 11(1),54-61.
  • Singh PK, Doley J, Ravi Kumar G, Sahoo AP, Tiwari AK, 2012: Oncolytic viruses & their specific targeting to tumour cells. Indian J Med Res, 136(4), 571-584.
  • Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB, 1956: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer, 9, 1211-1218.
  • Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R, 2001: A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res, 7, 120- 126.
  • Sze DY, Reid TR, Rose SC, 2013: Oncolytic virotherapy. J Vasc Interv Radiol, 24, 1115-1122.
  • Taylor MW, Cordell B, Souhrada M, Prather S, 1971: Viruses as an aid to cancer therapy: regression of solid and ascitestumors in rodents after treatment with bovine enterovirus. Proc Natl Acad Sci USA, 68, 836-840.
  • Todo T, Martuza RL, Rabkin SD, Johnson PA, 2001: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA, 98, 6396-6401.
  • Turnbull S, West EJ, Scott KJ, Appleton E, Melcher A, Ralph C, 2015: Evidence for oncolytic virotherapy: Where have we got to and where are we going? Viruses, 7(12), 6291-6312.
  • van Beusechem V, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR, 2002: Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res, 62, 6165-6171.
  • Varghese S, Rabkin SD, 2002: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther, 9, 967-978.
  • Vähä-Koskela MJ V, Heikkilä JE, Hinkkanen AE, 2007: Oncolytic viruses in cancer therapy. Cancer Lett, 254(2), 178-216.
  • Wheelock EF, Dingle JF, 1964: Observations on the repeated administration of viruses to a patient with acute leukemia: A preliminary report. New Engl J Med, 271, 645-651.
  • Wong HH, Lemoine NR, Wang Y, 2010: Oncolytic viruses for cancer therapy: Overcoming the obstacles. Viruses, 2(1), 78-106.
  • Yu W, Fang H, 2007, Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets, 7, 141-148.
APA KOÇ B, EROL N (2016). Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar. , 196 - 201.
Chicago KOÇ B. Taylan,EROL NURAL Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar. (2016): 196 - 201.
MLA KOÇ B. Taylan,EROL NURAL Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar. , 2016, ss.196 - 201.
AMA KOÇ B,EROL N Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar. . 2016; 196 - 201.
Vancouver KOÇ B,EROL N Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar. . 2016; 196 - 201.
IEEE KOÇ B,EROL N "Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar." , ss.196 - 201, 2016.
ISNAD KOÇ, B. Taylan - EROL, NURAL. "Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar". (2016), 196-201.
APA KOÇ B, EROL N (2016). Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar. Harran Üniversitesi Veteriner Fakültesi Dergisi, 5(2), 196 - 201.
Chicago KOÇ B. Taylan,EROL NURAL Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar. Harran Üniversitesi Veteriner Fakültesi Dergisi 5, no.2 (2016): 196 - 201.
MLA KOÇ B. Taylan,EROL NURAL Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar. Harran Üniversitesi Veteriner Fakültesi Dergisi, vol.5, no.2, 2016, ss.196 - 201.
AMA KOÇ B,EROL N Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar. Harran Üniversitesi Veteriner Fakültesi Dergisi. 2016; 5(2): 196 - 201.
Vancouver KOÇ B,EROL N Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar. Harran Üniversitesi Veteriner Fakültesi Dergisi. 2016; 5(2): 196 - 201.
IEEE KOÇ B,EROL N "Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar." Harran Üniversitesi Veteriner Fakültesi Dergisi, 5, ss.196 - 201, 2016.
ISNAD KOÇ, B. Taylan - EROL, NURAL. "Onkolitik Viroterapi ve Bazı Onkolitik Viruslar ile Yapılan Anti-Tümöral Uygulamalar". Harran Üniversitesi Veteriner Fakültesi Dergisi 5/2 (2016), 196-201.
Sayfa Oluşturulma Tarihi
23-04-2024 0:59

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları